These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22028089)

  • 21. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.
    Chatterjee D; Katz MH; Foo WC; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2017 Aug; 41(8):1097-1104. PubMed ID: 28614206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
    Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
    J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
    Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
    Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.
    Wang J; Estrella JS; Peng L; Rashid A; Varadhachary GR; Wang H; Lee JE; Pisters PW; Vauthey JN; Katz MH; Gomez HF; Evans DB; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Aug; 118(15):3801-11. PubMed ID: 22180096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histologic Tumor Grade and Preoperative Bilary Drainage are the Unique Independent Prognostic Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy.
    Macías N; Sayagués JM; Esteban C; Iglesias M; González LM; Quiñones-Sampedro J; Gutiérrez ML; Corchete LA; Abad MM; Bengoechea O; Muñoz-Bellvis L
    J Clin Gastroenterol; 2018 Feb; 52(2):e11-e17. PubMed ID: 28059940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
    Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
    Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.
    Zenali M; Overman MJ; Rashid A; Broaddus RB; Wang H; Katz MH; Fleming JB; Abbruzzese JL; Wang H
    Hum Pathol; 2013 Dec; 44(12):2792-8. PubMed ID: 24139211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma.
    Wang F; Gill AJ; Neale M; Puttaswamy V; Gananadha S; Pavlakis N; Clarke S; Hugh TJ; Samra JS
    Ann Surg Oncol; 2014 Jun; 21(6):1937-47. PubMed ID: 24558067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis.
    La Torre M; Cavallini M; Ramacciato G; Cosenza G; Rossi Del Monte S; Nigri G; Ferri M; Mercantini P; Ziparo V
    J Surg Oncol; 2011 Nov; 104(6):629-33. PubMed ID: 21713779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas.
    Banz VM; Croagh D; Coldham C; Tanière P; Buckels J; Isaac J; Mayer D; Muiesan P; Bramhall S; Mirza DF
    Eur J Surg Oncol; 2012 Jan; 38(1):72-9. PubMed ID: 22054617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility.
    Pang TC; Wilson O; Argueta MA; Hugh TJ; Chou A; Samra JS; Gill AJ
    Pathology; 2014 Apr; 46(3):188-92. PubMed ID: 24614707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study.
    Park Y; Han YB; Kim J; Kang M; Lee B; Ahn ES; Han S; Kim H; Na HY; Han HS; Yoon YS
    Pancreatology; 2024 Jun; 24(4):562-571. PubMed ID: 38556428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma.
    Jamieson NB; Denley SM; Logue J; MacKenzie DJ; Foulis AK; Dickson EJ; Imrie CW; Carter R; McKay CJ; McMillan DC
    Ann Surg Oncol; 2011 Aug; 18(8):2318-28. PubMed ID: 21267785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
    N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
    J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
    JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
    Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
    Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence.
    Tamburrino D; Arcangeli C; De Stefano F; Belfiori G; Macchini M; Orsi G; Schiavo Lena M; Partelli S; Crippa S; Doglioni C; Reni M; Falconi M
    Surgery; 2024 Nov; 176(5):1458-1465. PubMed ID: 39191599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.
    Ahn S; Lee JC; Kim J; Kim YH; Yoon YS; Han HS; Kim H; Hwang JH
    Gut Liver; 2022 Jan; 16(1):129-137. PubMed ID: 33875622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.